BIIB vs DMAC
BIIB: A pioneer in neuroscience and immunology, Biogen is a major biotechnology company focused on addressing high-unmet medical needs in complex diseases like Alzheimer’s, Multiple Sclerosis, and SMA. DMAC: DiaMedica Therapeutics is a clinical-stage biotech developing recombinant kallikrein-1 and ulinastatin protein therapies for the treatment of ischemic conditions like preeclampsia and stroke.
Side-by-side fundamentals
| Metric | BIIB | DMAC | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $240.98 | $8.69 | |
| Market cap | $35.6B | $469M | |
| P/E as of 2026-10-21 | 25.91 | n/a | |
| Net margin FY2025, SEC XBRL | +13.1% | n/a | |
| Operating margin FY2021, SEC XBRL | +25.9% | n/a | |
| ROE FY2025, SEC XBRL | +7.1% | -58.4% | BIIB higher |
| ROA FY2025, SEC XBRL | +4.4% | -53.4% | BIIB higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-03-31 | 0.34 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +2.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -0.9% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.50 | 1.40 | |
| 1-year return as of 2026-10-21 close | +64.8% | +31.3% | BIIB higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.